Novartis boosts forecast again as new gene therapy shines
Bloomberg Novartis AG raised its earnings forecast for the third time this year as new drugs including gene therapy Zolgensma got off to a strong start. Sales of the world’s most expensive drug beat analysts’ estimates with more than 100 children treated since Zolgensma’s May approval. Novartis said plans are in place covering about 90% of commercial patients and about ...
Read More »